Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?

Pharmacogenomics

Volumn 10, Issue 11, 2009, Pages 1729-1732

  Ansari, Marc ^a,b   Krajinovic, Maja ^b,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BUSULFAN; CORTICOSTEROID DERIVATIVE; CYSTEINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; GYRASE INHIBITOR; THREONINE;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; CANCER RECURRENCE; CHILDHOOD CANCER; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSFORMATION; EDITORIAL; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRASPECIFIC VARIATION; LIVER VENOOCCLUSIVE DISEASE; MYELOABLATIVE CONDITIONING; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN FUNCTION; RECURRENT DISEASE; THALASSEMIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; GLUTATHIONE TRANSFERASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 70649097095     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.135     Document Type: Editorial

References (33)

1. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998). (Pubitemid 28193431)
2. Relling MV, Pui CH, Cheng C, Evans WE: Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107(2), 843-844 (2006). (Pubitemid 43076417)
3. Guo Y, Shafer S, Weller P, Usuka J, Peltz G: Pharmacogenomics and drug development. Pharmacogenomics 6(8), 857-864 (2005).
4. van den Akker-van Marle ME, Gurwitz D, Detmar SB et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7(5), 783-792 (2006). (Pubitemid 44225913)
5. McCune JS, Gooley T, Gibbs JP et al.: Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 30(3), 167-173 (2002). (Pubitemid 34993856)
6. Vassal G, Koscielny S, Challine D et al.: Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 37(3), 247-253 (1996).
7. Dix SP, Wingard JR, Mullins RE et al.: Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 17(2), 225-230 (1996).
8. Slattery JT, Sanders JE, Buckner CD et al.: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 16(1), 31-42 (1995).
9. Bleyzac N, Souillet G, Magron P et al.: Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 28(8), 743-751 (2001). (Pubitemid 33089217)
10. Tran HT, Madden T, Petropoulos D et al.: Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 26(5), 463-470 (2000). (Pubitemid 30702302)
11. Bolinger AM, Zangwill AB, Slattery JT et al.: Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 28(11), 1013-1018 (2001).
12. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y: Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 37(4), 345-351 (2006). (Pubitemid 43250467)
13. Bartelink IH, Bredius RG, Belitser SV et al.: Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol. Blood Marrow Transplant. 15(2), 231-241 (2009).
14. Bartelink IH, Bredius RG, Ververs TT et al.: Once-daily intravenous busulfan with therapeutic drug monitoring compared with conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 14(1), 88-98 (2008).
15. Bleyzac N: The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam. Clin. Pharmacol. 22(6), 605-608 (2008).
16. Dalle JH, Wall D, Theoret Y et al.: Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant. 32(7), 647-651 (2003). (Pubitemid 37258619)
17. Nath CE, Earl JW, Pati N, Stephen K, Shaw PJ: Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br. J. Clin. Pharmacol. 66(1), 50-59 (2008). (Pubitemid 351822161)
18. Zwaveling J, Press RR, Bredius RG et al.: Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther. Drug Monit. 30(4), 504-510 (2008).
19. Kassir TD, Champagne MA, Duval M, Larocque D, Labbé L: Population pharmacokinetic of intravenous busulfan in children. Clin. Pharmacol. Ther. 81(Suppl. 1), S81 (2007).
20. Czerwinski M, Gibbs JP, Slattery JT: Busulfan conjugation by glutathione S-transferases α, μ, and π. Drug Metab. Dispos. 24(9), 1015-1019 (1996).
21. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J: Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase π gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem. 272(15), 10004-10012 (1997). (Pubitemid 27171673)
22. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6(9), 733-743 (1997).
23. Coles BF, Morel F, Rauch C et al.: Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11(8), 663-669 (2001). (Pubitemid 33078235)
24. Guy CA, Hoogendoorn B, Smith SK, Coleman S, O'Donovan MC, Buckland PR: Promoter polymorphisms in glutathione-S-transferase genes affect transcription. Pharmacogenetics 14(1), 45-51 (2004). (Pubitemid 38183961)
25. Morel F, Rauch C, Coles B, Le Ferrec E, Guillouzo A: The human glutathione transferase α locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 12(4), 277-286 (2002). (Pubitemid 34620655)
26. Ansari M, Lauzon-Joset JF, Vachon MF et al.: Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. (2009) (Epub ahead of print).
27. Srivastava A, Poonkuzhali B, Shaji RV et al.: Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104(5), 1574-1577 (2004). (Pubitemid 39166540)
28. Bredschneider M, Klein K, Murdter TE et al.: Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin. Pharmacol. Ther. 71(6), 479-487 (2002). (Pubitemid 34701355)
29. Johnson L, Orchard PJ, Baker KS et al.: Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J. Clin. Pharmacol. 48(9), 1052-1062 (2008).
30. Kusama M, Kubota T, Matsukura Y et al.: Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin. Chim. Acta 368(1-2), 93-98 (2006). (Pubitemid 43776023)
31. Kim I, Keam B, Lee KH et al.: Glutathione S-transferase A1 polymorphisms and acute graft-vs-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Clin. Transplant. 21(2), 207-213 (2007). (Pubitemid 46505728)
32. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 4(1), 66-72 (2004).
33. Rocha JC, Cheng C, Liu W et al.: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105(12), 4752-4758 (2005). (Pubitemid 40807300)